Gett Supports Safe Return of International Travel From the UK
17.5.2021 14:00:00 EEST | Business Wire | Press release
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is supporting the UK government Department for Transport and its Global Travel Taskforce with the safe return of international travel.
Gett’s ground transportation B2B marketplace now provides its clients with updates from the UK Government’s ‘traffic light’ system, supporting partners and users worldwide for the safe return of international travel. On its platform, Gett will update users with information on testing, quarantining, and travel restrictions to allow passengers access to information and government guidelines in relation to the next phase of re-opening the UK economy. This initiative supports Gett’s desire to assist employers to satisfy their duty of care obligations towards their employees, by providing users with access to information for safe travel.
As announced by the UK government on 9 April 2021, the ‘traffic light’ system applies different risk-based restrictions for passengers returning to the UK. Those travelling from ‘green’ countries require a negative Covid-19 test prior to departure but do not have to isolate when coming back into the UK, whilst travellers returning from ‘amber’ countries similarly require a negative pre-departure Covid-19, but also must isolate at home for 10 days upon their return and get a PCR test on days 2 and 8. Travellers from ‘red’ countries additionally require a negative Covid-19 test prior to departure and must isolate in specified hotels for 10 days.
Currently serving more than a quarter of Fortune 500 companies, Gett‘s unique position as a B2B marketplace for ground transportation management makes Gett a valuable partner for the UK government’s reopening of corporate travel. Gett has recently strengthened its international offering, with further expansion into the US market through the continued growth of global partner fleets. This includes the previously announced partnership with e-fleet operator Curb Mobility, joining a portfolio of existing corporate fleet, ride-hailing, taxi, and limo providers, including Lyft and Ola.
Andrew Verbitsky, Deputy CEO of Gett, commented: “The safe resumption of international travel is essential to restarting the corporate travel sector and supporting and enabling global economic recovery. Gett, as the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is uniquely positioned to be a valued partner in this important milestone for the UK and global economy. Gett is committed to the safe resumption of corporate travel for its B2B clients and their employees.”
About Gett
Gett is a technology platform solely focused on corporate Ground Transportation Management (GTM), a market worth $79.6B globally. https://bit.ly/2SEIV3M
Gett is the GTM category leader, serving over a quarter of the Fortune 500 companies.
Gett’s cloud-based software aggregates existing transportation providers onto a single platform, helping businesses manage all of their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally.
Gett organises corporate fleet, ride-hailing, taxi, and limo providers on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saving businesses time and money.
Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
-ENDS-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005435/en/
Contact information
FTI Consulting
Rob Mindell
Ollie Pratt
gett@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom